Paul Hartman

478 total citations
9 papers, 381 citations indexed

About

Paul Hartman is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Paul Hartman has authored 9 papers receiving a total of 381 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Oncology, 3 papers in Molecular Biology and 3 papers in Cancer Research. Recurrent topics in Paul Hartman's work include Angiogenesis and VEGF in Cancer (3 papers), Cancer Treatment and Pharmacology (3 papers) and Acute Myeloid Leukemia Research (2 papers). Paul Hartman is often cited by papers focused on Angiogenesis and VEGF in Cancer (3 papers), Cancer Treatment and Pharmacology (3 papers) and Acute Myeloid Leukemia Research (2 papers). Paul Hartman collaborates with scholars based in United States, Canada and Ireland. Paul Hartman's co-authors include Scot C. Remick, Afshin Dowlati, Jay Wasman, Pingfu Fu, Susan M. Flick, P. Savvides, Colin Mooney, Sanjiv S. Agarwala, Govardhanan Nagaiah and José Ortiz and has published in prestigious journals such as Clinical Cancer Research, Tetrahedron Letters and The American Journal of Surgery.

In The Last Decade

Paul Hartman

9 papers receiving 374 citations

Peers

Paul Hartman

ONCOL

MB

CR

EDM

OC

John Waas United States

Shinji Oie Japan

James Zweibel United States

Krista Menard United States

Jason L. Rowand United States

S. Kim United States

Sumiko Okubo Japan

Tadao Manabe Japan

A. Seun Ajiboye United States

Dawo Liu China

John Waas United States

Paul Hartman

193 ×1.2

ONCOL

261 ×1.8

MB

87 ×0.9

CR

59 ×0.8

EDM

72 ×1.0

OC

Citations per year, relative to Paul Hartman Paul Hartman (= 1×) peers John Waas

Countries citing papers authored by Paul Hartman

Since Specialization

Citations

This map shows the geographic impact of Paul Hartman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Hartman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Hartman more than expected).

Fields of papers citing papers by Paul Hartman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Hartman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Hartman. The network helps show where Paul Hartman may publish in the future.

Co-authorship network of co-authors of Paul Hartman

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Hartman. A scholar is included among the top collaborators of Paul Hartman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Hartman. Paul Hartman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

1.

Mooney, Colin, Govardhanan Nagaiah, Pingfu Fu, et al.. (2009). A Phase II Trial of Fosbretabulin in Advanced Anaplastic Thyroid Carcinoma and Correlation of Baseline Serum-Soluble Intracellular Adhesion Molecule-1 with Outcome. Thyroid. 19(3). 233–240. 153 indexed citations

2.

Baar, Joseph, Paula Silverman, Janice A. Lyons, et al.. (2009). A Vasculature-Targeting Regimen of Preoperative Docetaxel with or without Bevacizumab for Locally Advanced Breast Cancer: Impact on Angiogenic Biomarkers. Clinical Cancer Research. 15(10). 3583–3590. 80 indexed citations

3.

Barr, Paul M., Pingfu Fu, Hillard M. Lazarus, et al.. (2007). Antiangiogenic activity of thalidomide in combination with fludarabine, carboplatin, and topotecan for high-risk acute myelogenous leukemia. Leukemia & lymphoma. 48(10). 1940–1949. 14 indexed citations

4.

Overmoyer, Beth, Pingfu Fu, Charles L. Hoppel, et al.. (2007). Inflammatory Breast Cancer as a Model Disease to Study Tumor Angiogenesis: Results of a Phase IB Trial of Combination SU5416 and Doxorubicin. Clinical Cancer Research. 13(19). 5862–5868. 36 indexed citations

5.

Dowlati, Afshin, Kelly M. Robertson, Tomas Radivoyevitch, et al.. (2005). Novel Phase I Dose De-escalation Design Trial to Determine the Biological Modulatory Dose of the Antiangiogenic Agent SU5416. Clinical Cancer Research. 11(21). 7938–7944. 30 indexed citations

6.

Dowlati, Afshin, Hillard M. Lazarus, Paul Hartman, et al.. (2003). Phase I and correlative study of combination bryostatin 1 and vincristine in relapsed B-cell malignancies.. PubMed. 9(16 Pt 1). 5929–35. 38 indexed citations

7.

Overmoyer, Beth, Kelly M. Robertson, Jesse M. Lewin, et al.. (2001). A phase I pharmacokinetic and pharmacodynamic study of SU5416 and Adriamycin in inflammatory breast cancer. Breast Cancer Research and Treatment. 69(3). 13 indexed citations

8.

DePalma, Ralph G., Paul Hartman, & Charles A. Hubay. (1969). Cholesterol metabolism. The American Journal of Surgery. 117(5). 662–665. 5 indexed citations

9.

Pomerantz, Martin & Paul Hartman. (1968). Thermal rearrangement of 3-phenylcyclobutene. Tetrahedron Letters. 9(8). 991–993. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact